Financing vaccinations - The South African experience

Vaccine

Volumn 30, Issue SUPPL.3, 2012, Pages

  Blecher, Mark S ^a   Meheus, Filip ^b   Kollipara, Aparna ^a   Hecht, Robert ^c   Cameron, Neil A ^d   Pillay, Yogan ^e   Hanna, Luisa ^a  

^a National Treasury   (South Africa)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c RESULTS FOR DEVELOPMENT INSTITUTE   (United States)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e NATIONAL DEPARTMENT OF HEALTH   (South Africa)

Author keywords

Financing; Pneumococcal; Rotavirus; South Africa; Vaccinations

Indexed keywords

PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE;

AUTHORITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIARRHEA; FINANCE; GOVERNMENT; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; LOWEST INCOME GROUP; MORBIDITY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; ROTAVIRUS INFECTION; SCALE UP; SOUTH AFRICA; VACCINATION; WORLD HEALTH ORGANIZATION;

COST-BENEFIT ANALYSIS; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; PNEUMOCOCCAL VACCINES; ROTAVIRUS VACCINES; SOUTH AFRICA; VACCINATION;

EID: 84865617485     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.042     Document Type: Review

References (50)

1. UNICEF/WHO [Internet]. UN Inter-agency group for child mortality estimates. Available from: [cited 05.01.2012]. http://www.childmortality.org/.
2. Heller P.S. Understanding fiscal space 2005, International Monetary Fund, Washington, DC, Report no.: PDP/05/4.
3. Black R.E., Cousens S., Johnson H.L., Lawn J.E., Rudan I., Bassani D.G., et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010, 375:1969-1987.
4. Global Alliance for Vaccines and Immunisation (GAVI) Immunisation financing options: a resource for policy makers 2002, GAVI, Geneva.
5. England S., Kaddar M., Nigam A., Pinto M. Practice and policies on user fees for immunization in developing countries 2001, World Health Organization, Geneva, Report no.: WHO/V&B/01.07.
6. Kaddar M., Lydon P., Levine R. Financial challenges of immunization: a look at GAVI. Bulletin of the World Health Organization 2004, 82:697-702.
7. The World Bank and the GAVI Alliance. Immunization financing toolkit: a resource for policy-makers and program managers. 2010.
8. Ngcobo N.J., Cameron N.A. Introducing new vaccines into the childhood immunisation programme in South Africa. South African Journal of Epidemiology and Infection 2010, 25:3-4.
9. Republic of South Africa National treasury. Budget review 2011 2011, National Treasury, Pretoria.
10. Republic of South Africa National treasury. Intergovernmental fiscal review 2011 2011, National Treasury, Pretoria.
11. World Health Organization [Internet]. World Health Statistics. Available from: [cited 15.01.12]. http://www.who.int/gho/database/en/.
12. Council for Medical Schemes Annual report 2009-2010 2009, Council for Medical Schemes, Pretoria.
13. Republic of South Africa, Department of Health National health act (61/2003): policy on national health insurance. Government Gazette 2011, 554.
14. Saxenian H., Cornejo S., Thorien K., Hecht R., Schwalbe N. An analysis of how the GAVI alliance and low- and middle-income countries can share costs of new vaccines. Health Affairs 2011, 30:1122-1133.
15. aids2031 Cost and Financing Working Group The long run costs and financing of HIV/AIDS in South Africa 2010, Results for Development Institute, Washington, DC.
16. Haaker M. Fiscal dimensions of HIV/AIDS in South Africa 2011, World Bank, Washington, DC.
17. Government of South Africa Constitution of the Republic of South Africa 1993 1994, South African Government, Pretoria.
18. Republic of South Africa Department of Health. National Health Act 2004, Department of Health, Pretoria.
19. Lucero M.G., Dulalia V.E., Nillas L.T., Williams G., Parreno R.N., Nohynek H., et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on X-ray in children under two years of age. Cochrane Database of Systematic Reviews 2004, CD004977.
20. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. New England Journal of Medicine 2003, 349:1341-1348.
21. World Health Organization-Choosing Interventions that are cost-effective (WHO-CHOICE) [Internet]. Cost-effectiveness thresholds. Available from: [cited 15.01.12]. http://www.who.int/choice/costs/CER_thresholds/en/index.html.
22. Statistics South Africa Midyear population estimates 2010, Statistics South Africa, Pretoria.
23. UNICEF [Internet]. Supplies & logistics. Available from: [cited 06.10.11]. http://www.unicef.org/supply/.
24. PAHO Revolving Fund: vaccine and syringe prices for 2009. Immunization Newsletter 2009, 31:4-7.
25. Steele A.D., Peenze I., de Beer M.C., Pager C.T., Yeats J., Potgieter N., et al. Anticipating rotavirus vaccines: epidemiology and surveillance of rotavirus in South Africa. Vaccine 2003, 21:354-360.
26. Waggie Z., Hawkridge A., Hussey G.D. Review of rotavirus studies in Africa: 1976-2006. Journal of Infectious Diseases 2010, 202(Suppl.):S23-S33.
27. Soares-Weiser K., Goldberg E., Tamimi G., Pitan O.C., Leibovici L. Rotavirus vaccine for preventing diarrhoea. Cochrane Database of Systematic Reviews 2004, CD002848.
28. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and Reports 1999, 48:1-20.
29. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine 2006, 354:23-33.
30. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine 2006, 354:11-22.
31. Madhi S., Lerumo T., Louw C., Kirsten M., Neuzil K., Steele D., et al. Efficacy of human rotavirus vaccine RIX4414 (Rotarix™) in South African infants during the first year of life - an interim analysis. 8th international rotavirus symposium 2008.
32. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine 2010, 362:289-298.
33. Meeting of the diarrhoeal and enteric vaccines advisory committee, October 2008 - executive summary. Weekly Epidemiological Record 2009, 84:30-36.
34. Podewils L.J., Antil L., Hummelman E., Bresee J., Parashar U.D., Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. Journal of Infectious Diseases 2005, 192(Suppl. 1):S133-S145.
35. Fischer T.K., Anh D.D., Antil L., Cat N.D., Kilgore P.E., Thiem V.D., et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. Journal of Infectious Diseases 2005, 192:1720-1726.
36. Widdowson M.A., Meltzer M.I., Zhang X., Bresee J.S., Parashar U.D., Glass R.I. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007, 119:684-697.
37. Valencia-Mendoza A., Bertozzi S.M., Gutierrez J.P., Itzler R. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico. BMC Infectious Diseases 2008, 8:103.
38. International AIDS Vaccine Initiative (IAVI). Procurement and pricing of new vaccines for developing countries. Policy Brief #16. 2008.
39. World Health Organization Rotavirus vaccines. Weekly Epidemiological Record 2007, 82:285-295.
40. Center for Global Development Advance Market Commitment Working Group. Making markets for vaccines: ideas to action. Washington, DC: 2005.
41. UNICEF [Internet]. Vaccine price data. Available from: [cited 12.03.12]. http://www.unicef.org/supply/index_57476.html.
42. Nakamura M.M., Tasslimi A., Lieu T.A., Levine O., Knoll M.D., Russell L.B., et al. Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries. International Health 2011, 3:270-281.
43. Médecins sans Frontières. Untangling the web of antiretroviral price reductions 2010;12.
44. Republic of South Africa, National Treasury Instruction note on enhancing compliance monitoring and improving transparency and accountability in supply chain management 2011, National Treasury, Pretoria.
45. World Health Organization, UNICEF, National Department of Health. Report of the post introduction evaluation of new vaccines in South Africa 2011.
46. Republic of South Africa, Department of Health Annual report 2009/10 2010, Pretoria, South Africa.
47. Republic of South Africa, Department of Health Annual report 2008/09 2009, Pretoria, South Africa.
48. von Gottberg A., Cohen C., de Gouveia L., Quan V., Meiring S., Madhi S.A., et al. Trends in invasive pneumococcal disease after PCV7 introduction in South Africa. 12th international symposium on pneumococci and pneumococcal diseases 2012.
49. Madhi S., Groome M., Zar H., Kapongo C., Mulligan C., Moore D., et al. Effectiveness of penumococcal conjugate vaccine (PCV) against presumed bacerial pneumonia in South African HIV uninfected children: a case-control study. 12th international symposium on pneumococci and pneumococcal diseases 2012.
50. The commission on macroeconomics and health Macroeconomics and health: investing in health for economic development 2001, World Health Organization, Geneva.